MR EVALUATION OF THE PERICARDIUM AND CARDIAC MALIGNANCIES

Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients

The purpose of this review is to provide an overview of the essential role that cardiovascular magnetic resonance (CMR) has in the field of cardio-oncology. Recent findings: CMR has been increasingly used for early identification of cancer therapy related cardiac dysfunction (CTRCD) due to its precision in detecting subtle changes in cardiac function and for myocardial tissue characterization. Summary: CMR is able to identify subclinical CTRCD in patients receiving potentially cardiotoxic chemotherapy and guide initiation of cardio protective therapy. Multiparametric analysis with myocardial strain, tissue characterization play a critical role in understanding important clinical questions in cardio-oncology.

Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors

The number of breast cancer (BC) survivors has been increasing lately, due to the improvement in early detection strategies and oncological treatments. However, BC survivors are 3 times as likely to develop heart failure (HF) within 5 years of cancer diagnosis, and 7/100 of them will develop HF in a median follow-up of 8.5 years. Furthermore, HF in BC survivors has a worse prognosis compared to other causes of HF. Anthracyclines and trastuzumab have been proven to improve survival. However, they are also considered as the main causative factors of HF in BC survivors. Old patients, those with a pre-existing cardiovascular (CV) risk factors/disease, prior exposure to chemotherapy and radiotherapy are at increased risk. Serial evaluation of troponins and cardiac imaging parameters using echocardiography and cardiovascular magnetic resonance can significantly contribute to the early diagnosis of cardiac involvement before overt HF will develop. Assessment and immediate treatment of traditional CV risk factors is the first step for cardiotoxicity prevention. In BC survivors with known heart disease, the clinical stabilization is strongly recommended for cardiotoxicity prevention. Finally, in high-risk CV patients, primary prevention including cardioprotectants and/or CV drugs should be applied. According to recent studies, the early start of ACE inhibitors and β-blockers and the modification of anti-cancer treatment can prevent the decline in left ventricular ejection fraction. However, further multicenter studies are needed to establish both prevention and treatment protocols to successfully overcome HF development in BC survivors.

Cardiovascular Magnetic Resonance in the Oncology Patient

Patients with or receiving potentially cardiotoxic treatment for cancer are susceptible to developing decrements in left ventricular mass, diastolic function, or systolic function. They may also experience valvular heart disease, pericardial disease, or intracardiac masses. Cardiovascular magnetic resonance may be used to assess cardiac anatomy, structure, and function and to characterize myocardial tissue. This combination of features facilitates the diagnosis and management of disease processes in patients with or those who have survived cancer. This report outlines and describes prior research involving cardiovascular magnetic resonance for assessing cardiovascular disease in patients with or previously having received treatment for cancer.

The Role of Cardiovascular Magnetic Resonance in the Management of Patients with Cancer

PURPOSE OF REVIEW

This article reviews the utility of cardiovascular magnetic resonance imaging (CMR) to detect abnormalities of the cardiovascular system that may result from cancer or its treatment.

RECENT FINDINGS

With CMR, one may assess cardiac anatomy, function, myocardial perfusion, tissue composition, and blood flow. For those with cancer, these capabilities allow one to differentiate myocardial masses that may relate to the presence of cancer and evaluate diseases of the pericardium. These features facilitate measurement of left ventricular (LV) volumes, ejection fraction, mass, strain, T1 and T2 relaxation properties, and the extracellular volume fraction all of which may be useful for detecting subclinical cardiovascular injury that results from the receipt of potentially cardiotoxic cancer treatment. CMR can provide an effective and efficient means to identify clinical abnormalities resulting from the diagnosis of cancer or subclinical cardiac injury that may be related to receipt of the therapy for cancer.

The presurgical T staging of non-small cell lung cancer: efficacy comparison of 64-MDCT and 3.0 T MRI

Background

Lung cancer has been the main concern of the cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) is reported the most common subtype of lung cancer. Initial staging of NSCLC is highly associated with the choice of treatment and prognosis of the patients. This study aims to prospectively compare the diagnostic efficacies of 64-multidetector-row computed tomography (MDCT) and 3.0 T magnetic resonance imaging (MRI) in T staging of NSCLC. 

Methods

Institutional review board approval and informed consent were obtained. Forty-five patients diagnosed with NSCLC who underwent preoperative MRI and MDCT scans were enrolled in the study. The efficacies of determination of T staging on MRI and MDCT were compared by using the McNemar test.

Results

Of 45 patients diagnosed with NSCLC, the primary tumors were correctly staged in 38 (84.4 %) patients on MDCT, and in 37 (82.2 %) patients on MRI. There was no statistically significant difference between the two modalities in the overall T staging of NSCLC with the reference of pathological findings (p = 0.564). However, MDCT was indicated more accurate in determination of NSCLC staged T1 and T2 (100 % vs 75 %, 96.4 % vs 82.1 %), whereas MRI was presented slightly superior in identification of NSCLC staged T3 and T4 (80 % vs 50 %, 100 % vs 33.3 %).

Conclusion

Both MDCT and MRI provided acceptable overall accuracies in determination of T staging in NSCLC. Furthermore, MRI was presented slight superiority for the advanced-stage tumors (i.e., NSCLC staged T3 and T4), whereas MDCT was indicated mild acceptance for the limited-stage tumors (i.e., NSCLC staged T1 and T2).

Usefulness of thin-section single-shot turbo spin echo with half-Fourier acquisition in evaluation of local invasion of lung cancer

PURPOSE

To evaluate the usefulness of thin-section single-shot turbo spin echo with half-Fourier acquisition (SS-TSE-HF) alone for evaluation of local invasion of lung cancer.

MATERIALS AND METHODS

Our Institutional Review Board approved this retrospective study. Thirty-six patients with lung cancer who underwent magnetic resonance imaging (MRI) for evaluation of local invasion followed by curative surgery from July 2008 to June 2012 were enrolled in this study. Two reviewers independently and blindly reviewed computed tomography (CT) and MRI (thin-section SS-TSE-HF and conventional MRI, which consisted of conventional axial SS-TSE-HF, dynamic MRI with respiratory and/or cardiac cine, and T1 -weighted high-resolution isotropic volume examination [THRIVE]) for the presence of local invasion. Diagnostic performances were evaluated using gross surgical findings and pathological results as a standard reference.

RESULTS

The overall diagnostic performance for detecting local invasion of lung cancer between the two reviewers were as follows: specificity and accuracy of thin-section SS-TSE-HF (89.0% and 87.5%) were significantly higher than those of CT (25.6% and 46.9%, P < 0.001 for both) or conventional MRI (61.0% and 69.5%, P < 0.001 and P = 0.008, respectively). Sensitivity was 84.8% for thin-section SS-TSE-HF with the same value for CT (P = 0.246) and conventional MRI (P = 0.209).

CONCLUSION

Thin-section SS-TSE-HF sequence alone without any contrast agent demonstrated a relatively high diagnostic performance in evaluation of local invasion of lung cancer.

Optimal imaging protocols for lung cancer staging: CT, PET, MR imaging, and the role of imaging

Chest radiography, the most commonly performed imaging technique for the detection of lung disease, is limited in accurately detecting early lung cancer. The main imaging modality for the staging of lung cancer is computed tomography (CT), supplemented by positron emission tomography (PET), usually as a hybrid technique in conjunction with CT (PET/CT). Magnetic resonance (MR) imaging is a useful diagnostic tool for specific indications and has the advantage of not using ionizing radiation. This article discusses the optimal imaging protocols for lung cancer staging using CT, PET (PET/CT), and MR imaging, and the role of imaging in patient management.

Constrictive pericarditis and restrictive cardiomyopathy in the modern era

The differentiation between constrictive pericarditis and restrictive cardiomyopathy can be clinically challenging. Pericardial constriction results from scarring and consequent loss of pericardial elasticity leading to impaired ventricular filling. Restrictive cardiomyopathy is characterized by a nondilated rigid ventricle, severe diastolic dysfunction and restrictive filling producing hemodynamic changes, similar to those in constrictive pericarditis. While constrictive pericarditis is usually curable by surgical treatment, restrictive cardiomyopathy requires medical therapy and in appropriate patients, the definitive treatment is cardiac transplantation. Sufficient differences exist between the two conditions to allow noninvasive differentiation, but no single diagnostic tool can be relied upon to make this distinction. Newer echocardiographic techniques such as speckle-track imaging, velocity vector imaging, as well as cardiac computed tomography and cardiac MRI can help differentiate constriction from restriction with high sensitivity and specificity. Outcomes are better with early diagnosis of constriction in particular and early surgical resection.

Recent technological and application developments in computed tomography and magnetic resonance imaging for improved pulmonary nodule detection and lung cancer staging

This review compares the emerging technologies and approaches in the application of magnetic resonance (MR) and computed tomography (CT) imaging for the assessment of pulmonary nodules and staging of malignant findings. Included in this review is a brief definition of pulmonary nodules and an introduction to the challenges faced. We have highlighted the current status of both MR and CT for the early detection of lung nodules. Developments are detailed in this review for the management of pulmonary nodules using advanced imaging, including: dynamic imaging studies, dual energy CT, computer aided detection and diagnosis, and imaging assisted nodule biopsy approaches which have improved lung nodule detection and diagnosis rates. Recent advancements linking in vivo imaging to corresponding histological pathology are also highlighted. In vivo imaging plays a pivotal role in the clinical staging of pulmonary nodules through TNM assessment. While CT and positron emission tomography (PET)/CT are currently the most commonly clinically employed modalities for pulmonary nodule staging, studies are presented that highlight the augmentative potential of MR.

Referrals to a dedicated cardiac MRI service: who sends what?

The purpose of this study was to retrospectively evaluate the referral patterns to the authors' cardiac magnetic resonance imaging service in its first 28 months of operation. In late November 2003, the authors' radiology practice established a cardiac magnetic resonance imaging service for a 719-bed teaching hospital and a 247-bed community hospital. Data relevant to referrals were reviewed. Between December 1, 2003, and April 1, 2006, 780 patients were imaged, 556 (71%) at the teaching hospital. Referrals came from 157 physicians in 17 different medical specialties, including adult cardiology (64%), cardiothoracic surgery (15%), pediatric cardiology (8%), internal medicine (6%), and others (7%). Overall, primary indications were function and viability evaluation (29%), aorta and valve assessment (24%), congenital heart disease (17%), arrhythmogenic right ventricular dysplasia exclusion (13%), cardiac masses (9%), pericardial disease (4%), and others (4%). Referrals for function and viability represented a much greater percentage of cases at the community hospital (53%) than at the teaching hospital (19%). The reverse was true for congenital heart disease (7% vs 21%). This study demonstrates that cardiac specialists generate the vast majority of referrals (87%) to the authors' cardiac magnetic resonance imaging service and that there are substantial differences in the referral patterns between a large teaching hospital and a smaller community hospital.

CT and MR imaging findings of benign cardiac tumors

This imaging review describes the appearance of benign cardiac tumors on CT and MRI. Although rare, benign tumors outnumber their primary malignant counterparts three to one. Since mortality varies directly with invasion, identifying the neoplasm at an early stage helps focus treatment, especially in benign cases, which generally respond well to surgical resection. In adults and children, myxomas and rhabdomyomas, respectively, represent the most common benign tumors, which can be grouped into tissue-specific subtypes, such as rhabdomyomas, fibromas, lipomas, teratomas, etc. Besides their variable prevalence in particular age groups, these tumors also differ with regard to their gender predilection, location, and number. For example, myxomas appear predominantly in women and generally as a solitary mass in the left or right atrium, whereas rhabdomyomas present equally in boys and girls and chiefly as multiple masses in the ventricles. Despite their differences, however, both types share an association with heritable syndromes like the Carney complex for myxomas and tuberous sclerosis for rhabdomyomas. As with all cardiac tumors, echocardiographic findings usually suggest the initial diagnosis but cross-sectional imaging with CT and MRI can help resolve diagnostically challenging cases. For example, with its direct multiplanar capability, excellent contrast resolution, and large field of view, MRI permits a detailed examination of the entire mediastinum, helping to rule out an equivocal mass on echocardiography. Through dynamic techniques, MRI, in addition to morphologic characterization, can depict the pathophysiological effects of these tumors, for instance, with regard to myocardial contraction, valvular function, or blood flow.

Calcifications of the heart

Cardiac calcification usually represents the result of a pathologic process. Some forms of calcification represent chronic change in an ageing population, and must be differentiated from pathologic calcification. Still other forms of calcification are associated with ageing and chronic degeneration, but also reflect ongoing pathologic processes. Recognition of cardiac calcification may be an early sign or only sign of a pathologic process. Characterization of the calcification in terms of its distribution and appearance is a helpful means for determining which structures are calcified, differentiating pathologic from nonpathologic processes. This article provides an overview of the types of calcifications of the heart, pathogenesis, and utility of the various imaging modalities for their detection.

Role of magnetic resonance imaging for evaluation of tumors in the cardiac region

The aim of this study was to review the role of MRI in the assessment of heart neoplasm, 25 cases with heart neoplasm (10 myxoma, 6 rhabdomyoma, 5 angiosarcoma, 2 mesothelioma, 1 lymphoma, and 1 fibroma) were examined with MRI and echocardiography. Multislice T1- and T2-weighted spin-echo images and static gradient-echo images were taken in appropriate directions with electrocardiogram gating. Gadolinium enhancement was performed in 21 cases. Transthoracic echocardiography was performed in all cases. Except for the 5 patients with rhabdomyoma, the pathological diagnosis was obtained. MRI proved to be useful for tissue characterization of myxoma, angiosarcoma, mesothelioma, and fibroma in cases with tuberous sclerosis. MRI also proved to be useful for detection of the tumor, depiction of contour, relation with other cardiac structures, in cases with myxoma, angiosarcoma, mesothelioma, lymphoma, and fibroma. In the differential diagnosis, MRI provided important information in cases with myxoma, rhabdomyoma, angiosarcoma, and fibroma. In cases with tumors expanding into the mediastinum, such as mesothelioma and fibroma in this report, MRI was useful in determining the location and border. In cases with tumors adjacent to pericardium, MRI was useful in detecting pericardial invasion. Gadolinium enhancement added useful information in cases with myxoma, rhabdomyoma, angiosarcoma, and mesothelioma. The role of MRI with and without Gd enhancement differs somewhat in individual types of heart neoplasm, and adaptation must be considered in each kind of neoplasm. On the other hand, MRI is an essential examination in all cases with a cardiac mass, which has not been diagnosed, since it may provide useful information for the differential diagnosis.

MR imaging of lung cancer

Since publication of the Radiologic Diagnostic Oncology Group Report in 1991, the clinical application of pulmonary magnetic resonance (MR) imaging to patients with lung cancer has been limited. Computed tomography has been much more widely available for staging of lung cancer in clinical situations. Currently, ventilation and perfusion scintigraphy is the only modality that demonstrates pulmonary function while 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography is the only modality that reveals biological glucose metabolism of lung cancer. However, recent advancements in MR imaging have made it possible to evaluate morphological and functional information in lung cancer patients more accurately and quantitatively. Pulmonary MR imaging may hold significant potential to substitute for nuclear medicine examinations. In this review, we describe recent advances in MR imaging of lung cancer, focusing on (1) characterization of solitary pulmonary nodules; (2) differentiation from secondary change; evaluation of (3) medastinal invasion, (4) chest wall invasion, (5) lymph node metastasis, and (6) distant metastasis; and (7) pulmonary functional imaging. We believe that further basic studies, as well as clinical applications of newer MR techniques, will play an important role in the management of patients with lung cancer.

Primary cardiac and pericardial neoplasms: radiologic-pathologic correlation

Primary cardiac and pericardial neoplasms are rare lesions and include both benign and malignant histologic types. Myxoma is the most frequent primary cardiac neoplasm, but other benign tumors include papillary fibroelastoma, rhabdomyoma, fibroma, hemangioma, lipoma, and paraganglioma. Cardiac sarcoma represents the second most common primary cardiac neoplasm. Lymphoma can also affect the heart primarily. Pericardial tumors that affect the heart include benign teratomas and malignant mesotheliomas. Patients affected with cardiac or pericardial neoplasms often present with cardiovascular compromise or embolic phenomena and exhibit cardiomegaly at chest radiography. Benign cardiac tumors typically manifest as intracavitary, mural, or epicardial focal masses, whereas malignant tumors demonstrate invasive features and may involve the heart diffusely. Benign lesions can usually be successfully excised, but patients with malignant lesions have an extremely poor prognosis.

[Treatment of malignant pericardial effusion]

Malignant pericardial effusion (MPE) presents as a clinical spectrum that ranges from totally asymptomatic to acute cardiac tamponade. Primary malignancies with a propensity for cardiac involvement include lung cancer, breast cancer, and lymphomas. Echocardiography is one of the most specific and sensitive non-invasive tests in the evaluation of MPE. Pericardiocentesis is both a diagnostic and therapeutic tool in the management of MPE. Several non-specific sclerosing agents are available for instillation into the pericardium to prevent a recurrence of pericardial effusion. Mechanical interventions including different surgical approaches are also highly effective. Ultimately, therapy of MPE must be individualized according to the patient's clinical condition and underlying malignancy. The main goal of therapy is to achieve lasting relief from effusion recurrence as quickly and as safely as possible.